Loading news...
The Dow Jones Industrial Average itself yields modestly, but the Dogs of the Dow 2026 pack more dividend bite. The index's top payers dish up to 6.8%.
Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were also seen in patients with liver metastases, who often face poorer outcomes with this disease RARITAN, N.J., Jan. 10, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new longer follow-up results from the investigational Phase 1b/2 OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody targeting epidermal growth factor receptor (EGFR) and MET, in combination with FOLFOX or FOLFIRI chemotherapy in patients with RAS/BRAF wild-type metastatic colorectal cancer.
Verizon stands out as the only Dow stock meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its single share price. Analyst projections suggest the top ten Dow Dogs could deliver an average 23.55% net gain by January 2027, with varying risk profiles. Yield-based strategies favor underdogs; price drops or dividend hikes could bring more Dow Dogs into fair-value territory for income-focused investors.
Cerity Partners LLC lowered its holdings in shares of Johnson and Johnson (NYSE: JNJ) by 1.6% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,782,644 shares of the company's stock after selling 28,920 shares during the period. Johnson and
Stock News California billionaire tax splits tech leaders: Nvidia (NVDA) CEO Jensen Huang said he's âfineâ with a proposed one-time 5% California wealth tax
Johnson and Johnson (JNJ) is making a very Washington style trade off. The company said it has reached an agreement with the Trump administration to lower drug pr
JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic manufacturing.
AbbVie and Johnson & Johnson have resilient, noncyclical businesses. They are also outstanding dividend payers.
CNBC's Jim Cramer delivers his daily Mad Dash.
Stock News xAI under fire over Grok image edits: Elon Musk's xAI (private) restricted Grok's image generation/editing on X to paying users after the tool was us
TSM enjoys revenue surge, Nvidia adds CMO for brand recognition, jobs report due, and more
Trump administration secures deal with Johnson & Johnson to reduce price of some medicines
Johnson and Johnson struck a deal with the Trump administration to lower drug prices for U.S. consumers in exchange for exemptions from tariffs.
Almanack Investment Partners LLC. grew its holdings in Johnson and Johnson (NYSE: JNJ) by 29.6% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 13,074 shares of the company's stock after buying an additional 2,985 shares during the quarter. Almanack Investment
The agreement provides Johnson & Johnson's pharmaceutical products an exemption from tariffs, the company said.
Johnson & Johnson said on Thursday it has reached a agreement with U.S. President Donald Trump's administration to cut drug prices for Americans in exchange for exemptions from U.S. tariffs.
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare's leading, most comprehensive innovation powerhouse, today announced a voluntary agreement with the Trump Administration to improve access to medicines and lower costs for millions of American patients. The joint agreement meets the requests laid out by President Trump to the industry and provides the Company's pharmaceutical products an exemption from tariffs1. “Today's agreement shows that when.
JNJ's Innovative Medicine segment shows resilience ahead of Q4 results, with key drugs driving growth despite Stelara biosimilars and Part D headwinds.
CWA Asset Management Group LLC decreased its holdings in Johnson and Johnson (NYSE: JNJ) by 17.4% during the undefined quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 99,944 shares of the company's stock after selling 21,081 shares during the quarter. Johnson and Johnson accounts
Daymark Wealth Partners LLC lifted its stake in Johnson and Johnson (NYSE: JNJ) by 6.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 212,719 shares of the company's stock after acquiring an additional 13,662 shares during the quarter. Johnson and Johnson makes